Bayer to Present Latest Research on Menopausal Sleep Disturbances at IMS 2024
Bayer is set to showcase its latest research on menopause symptoms, particularly sleep disturbances, at the 19th World Congress of the International Menopause Society (IMS) from October 19-22, 2024, in Melbourne, Australia. The new data reveals that 40% to 60% of women experience sleep disturbances during the menopausal transition, significantly affecting their quality of life, work productivity, and overall well-being.
This year’s presentations include a pooled analysis and several subgroup analyses from the Phase III OASIS 1 and 2 studies involving the investigational compound elinzanetant. These findings highlight Bayer’s commitment to addressing unmet medical needs in women’s healthcare, particularly regarding menopause.
Key Presentations by Bayer:
- Oral Presentations:
- “Vasomotor Symptoms and the Impact of Sleep Disturbance Among Postmenopausal Women in Europe”
Speaker: Pauline Maki
Date: October 21, 2024, 15:50 to 17:20 AEST, Room 210 - “Exploring Sleep Disturbances Across Age and Sex with Wearable Smartwatches”
Speaker: Claudio Soares
Date: October 21, 2024, 15:50 to 17:20 AEST, Room 210 - Scientific Symposia:
“Looking Beyond VMS: Sleep Disturbances in Menopause”
Speakers: Claudio Soares, Susan Davis, Pauline Maki, and Paula Briggs
Date: October 20, 2024, 15:15 – 16:45 AEST, Room 203 - Posters:
Various posters will explore topics such as the impact of sleep disturbance on depression and anxiety, co-occurrence of vasomotor symptoms and sleep disturbances, and the effects of elinzanetant across different demographics.
Sleep disturbances, alongside vasomotor symptoms like hot flashes, are among the most common and disruptive symptoms experienced during menopause. These disturbances can hinder women’s daily activities, affecting their quality of life and potentially leading to longer-term health issues, including metabolic changes and cognitive decline.
Bayer is developing elinzanetant, the first dual neurokinin-1 and 3 (NK-1 and 3) receptor antagonist in late-stage clinical trials for the non-hormonal treatment of moderate to severe vasomotor symptoms associated with menopause. Recent studies, including OASIS 1 and 2, have shown promising efficacy and safety results for elinzanetant, leading to New Drug Applications currently under review in several countries, including the US and the EU.
Additionally, Bayer is conducting the Phase II NIRVANA study to evaluate the efficacy and safety of elinzanetant as a treatment for menopause-associated sleep disturbances. Bayer’s collaboration with Samsung aims to utilize data from wearable devices to further understand sleep issues in menopausal women.
For more details on the conference program, visit the IMS congress website.
About Bayer
Bayer is a global leader in women’s healthcare, committed to developing innovative treatments and addressing the unique needs of women. With a focus on sustainability, Bayer aims to improve health outcomes and expand access to healthcare solutions worldwide.
About Elinzanetant
Elinzanetant is an investigational medication targeting the treatment of vasomotor symptoms associated with menopause by modulating estrogen-sensitive neurons in the brain.
About Menopause
The number of women experiencing menopause is expected to reach 1.2 billion globally by 2030, highlighting the need for effective treatments for symptoms that can significantly affect their quality of life.
